Steven R. Loranger's most recent trade in Edwards Lifesciences Corp was a trade of 3,251 Common Stock done . Disclosure was reported to the exchange on May 8, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Edwards Lifesciences | Steven R. Loranger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2026 | 3,251 | 7,933 (0%) | 0% | 0 | Common Stock | |
| Edwards Lifesciences | Steven R. Loranger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2026 | 1,064 | 8,997 (0%) | 0% | 0 | Common Stock | |
| Edwards Lifesciences | Steven R. Loranger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2025 | 3,528 | 63,900 (0%) | 0% | 0 | Common Stock | |
| Edwards Lifesciences | Steven R. Loranger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2025 | 1,154 | 65,054 (0%) | 0% | 0 | Common Stock | |
| Edwards Lifesciences | Steven R. Loranger | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 45.32 per share. | 14 Feb 2025 | 5,739 | 66,111 (0%) | 0% | 45.3 | 260,073 | Common Stock |
| Edwards Lifesciences | Steven R. Loranger | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 5,739 | 0 | - | - | Director Stock Option (Right to Acquire) | |
| Edwards Lifesciences | Steven R. Loranger | Director | Sale of securities on an exchange or to another person at price $ 76.42 per share. | 14 Feb 2025 | 5,739 | 60,372 (0%) | 0% | 76.4 | 438,576 | Common Stock |
| Edwards Lifesciences | Steven R. Loranger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2024 | 3,055 | 59,373 (0%) | 0% | 0 | Common Stock | |
| Edwards Lifesciences | Steven R. Loranger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2024 | 999 | 60,372 (0%) | 0% | 0 | Common Stock | |
| Xylem | Steven R. Loranger | Director | 18 May 2023 | 1,580 | 13,818 (0%) | 0% | 0 | Common Stock | ||
| Edwards Lifesciences | Steven R. Loranger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2023 | 2,803 | 55,420 (0%) | 0% | 0 | Common Stock | |
| Edwards Lifesciences | Steven R. Loranger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2023 | 898 | 56,318 (0%) | 0% | 0 | Common Stock | |
| Xylem | Steven R. Loranger | Director | 12 May 2022 | 1,812 | 12,238 (0%) | 0% | 0 | Common Stock | ||
| Edwards Lifesciences | Steven R. Loranger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 2,300 | 51,880 (0%) | 0% | 0 | Common Stock | |
| Edwards Lifesciences | Steven R. Loranger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 737 | 52,617 (0%) | 0% | 0 | Common Stock | |
| Xylem | Steven R. Loranger | Director | 31 Dec 2021 | 12,491 | 46,407 (0%) | 0% | 0 | Common Stock |